Total Payments
$3.0M
2024 Payments
$601,275
Companies
42
Transactions
4,552
Medicare Patients
8,788
Medicare Billing
$974,281
Payment Breakdown by Category
Other$2.2M (70.8%)
Consulting$423,518 (13.9%)
Travel$302,468 (10.0%)
Food & Beverage$96,867 (3.2%)
Research$62,227 (2.0%)
Education$687.44 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.1M | 711 | 69.8% |
| Consulting Fee | $423,518 | 152 | 13.9% |
| Travel and Lodging | $302,468 | 1,049 | 10.0% |
| Food and Beverage | $96,867 | 2,601 | 3.2% |
| Unspecified | $62,227 | 8 | 2.0% |
| Honoraria | $28,000 | 8 | 0.9% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $4,600 | 2 | 0.2% |
| Education | $687.44 | 19 | 0.0% |
| Compensation for serving as faculty or as a speaker for a medical education program | $414.23 | 2 | 0.0% |
Payments by Type
General
$3.0M
4,544 transactions
Research
$62,227
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $496,090 | 694 | $0 (2024) |
| Lilly USA, LLC | $382,316 | 540 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $315,931 | 599 | $0 (2024) |
| Celgene Corporation | $271,404 | 263 | $0 (2022) |
| Amgen Inc. | $189,804 | 287 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $171,211 | 161 | $0 (2024) |
| GENZYME CORPORATION | $161,764 | 175 | $0 (2024) |
| Janssen Biotech, Inc. | $157,535 | 441 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $152,999 | 209 | $0 (2024) |
| Incyte Corporation | $137,791 | 174 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $601,275 | 758 | ABBVIE INC. ($101,442) |
| 2023 | $611,983 | 840 | Incyte Corporation ($74,449) |
| 2022 | $329,156 | 605 | Lilly USA, LLC ($86,694) |
| 2021 | $187,111 | 361 | AbbVie Inc. ($49,348) |
| 2020 | $171,309 | 225 | AbbVie Inc. ($34,067) |
| 2019 | $397,766 | 628 | Celgene Corporation ($88,788) |
| 2018 | $400,584 | 585 | Celgene Corporation ($125,686) |
| 2017 | $339,182 | 550 | Novartis Pharmaceuticals Corporation ($117,334) |
All Payment Transactions
4,552 individual payment records from CMS Open Payments — Page 1 of 183
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $17.81 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/19/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $124.62 | General |
| Category: Immunology | ||||||
| 12/18/2024 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,930.00 | General |
| Category: Inflammation | ||||||
| 12/18/2024 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,310.00 | General |
| Category: Inflammation | ||||||
| 12/18/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $1,195.05 | General |
| 12/18/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $321.76 | General |
| 12/18/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $240.48 | General |
| 12/18/2024 | Ortho Dermatologics, a division of Bausch Health US, LLC | SILIQ (Drug) | Food and Beverage | In-kind items and services | $23.04 | General |
| Category: Dermatology | ||||||
| 12/17/2024 | UCB, Inc. | Bimzelx (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,000.00 | General |
| Category: Immunology | ||||||
| 12/17/2024 | UCB, Inc. | Bimzelx (Biological) | Consulting Fee | Cash or cash equivalent | $2,250.00 | General |
| Category: Immunology | ||||||
| 12/17/2024 | Ortho Dermatologics, a division of Bausch Health US, LLC | SILIQ (Drug) | Food and Beverage | In-kind items and services | $20.89 | General |
| Category: Dermatology | ||||||
| 12/17/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $16.86 | General |
| Category: Immunology | ||||||
| 12/16/2024 | UCB, Inc. | Bimzelx (Biological) | Travel and Lodging | In-kind items and services | $185.90 | General |
| Category: Immunology | ||||||
| 12/16/2024 | UCB, Inc. | Bimzelx (Biological) | Travel and Lodging | In-kind items and services | $40.00 | General |
| Category: Immunology | ||||||
| 12/13/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $24.91 | General |
| Category: Immunology | ||||||
| 12/12/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | SPEVIGO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,210.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/11/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Travel and Lodging | Cash or cash equivalent | $95.14 | General |
| Category: Immunology | ||||||
| 12/11/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | Cash or cash equivalent | $43.07 | General |
| Category: Immunology | ||||||
| 12/11/2024 | Ortho Dermatologics, a division of Bausch Health US, LLC | SILIQ (Drug) | Food and Beverage | In-kind items and services | $36.32 | General |
| Category: Dermatology | ||||||
| 12/11/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | Cash or cash equivalent | $6.44 | General |
| Category: Immunology | ||||||
| 12/11/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | Cash or cash equivalent | $4.96 | General |
| Category: Immunology | ||||||
| 12/10/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $90.08 | General |
| Category: Dermatology | ||||||
| 12/10/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $34.00 | General |
| Category: Immunology | ||||||
| 12/09/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $558.89 | General |
| 12/09/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $291.20 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double Blind-Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis (CC-10004-PSOR-025) | Celgene Corporation | $27,684 | 1 |
| AP-CL-LICPLAN-PI-006599 - Open Label Trial evaluating the efficacy of Apremilast for the treatment of frontal fribrosing alopecia | Celgene Corporation | $21,545 | 1 |
| Open Label Trial evaluating the efficacy of Apremilast for the treatment of frontal fribrosing alopecia (AP-CL-LICPLAN-PI-006599) | Celgene Corporation | $4,710 | 1 |
| An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis (DISCREET) | Amgen Inc. | $4,346 | 1 |
| PSOSA (PSORIASIS SPECIAL AREAS) - A US-BASED SINGLE-ARM PROSPECTIVE MULTICENTER OBSERVATIONAL STUDY OF NAIL AND SCALP PSORIASIS IMPROVEMENT IN PATIENTS TREATED WITH IXEKIZUMAB | Eli Lilly and Company | $2,076 | 1 |
| An Efficacy and Safety Study of Apremilast CC-10004 in Subjects With Moderate to Severe Genital Psoriasis DISCREET | Amgen Inc. | $1,726 | 1 |
| EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | Eli Lilly and Company | $104.58 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 21 | 2,290 | 4,686 | $660,180 | $260,389 |
| 2022 | 22 | 2,759 | 5,469 | $691,668 | $295,702 |
| 2021 | 24 | 2,392 | 4,768 | $514,968 | $259,029 |
| 2020 | 12 | 1,347 | 2,998 | $315,102 | $159,161 |
Total Patients
8,788
Total Services
17,921
Medicare Billing
$974,281
Procedure Codes
79
All Medicare Procedures & Services
79 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 96910 | Therapy procedure using ultraviolet radiation with tar or petroleum jelly application | Office | 2023 | 21 | 540 | $156,600 | $59,749 | 38.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 580 | 873 | $102,560 | $59,307 | 57.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 197 | 249 | $43,251 | $24,394 | 56.4% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 251 | 289 | $83,483 | $23,294 | 27.9% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 374 | 497 | $119,280 | $22,300 | 18.7% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 132 | 158 | $29,374 | $15,709 | 53.5% |
| 12032 | Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | Office | 2023 | 41 | 41 | $20,461 | $11,066 | 54.1% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 285 | 1,557 | $19,463 | $9,339 | 48.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 99 | 99 | $17,198 | $7,505 | 43.6% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 73 | 87 | $8,265 | $3,845 | 46.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 27 | 27 | $7,093 | $3,336 | 47.0% |
| 17262 | Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | Office | 2023 | 24 | 24 | $6,878 | $3,336 | 48.5% |
| 17282 | Destruction of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm | Office | 2023 | 16 | 19 | $6,314 | $3,297 | 52.2% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 18 | 24 | $5,915 | $3,287 | 55.6% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 55 | 65 | $10,138 | $3,006 | 29.7% |
| 11602 | Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | Office | 2023 | 21 | 21 | $8,517 | $2,561 | 30.1% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 17 | 17 | $6,173 | $1,882 | 30.5% |
| 11900 | Injection into skin growth, 1-7 growths | Office | 2023 | 16 | 31 | $2,818 | $1,271 | 45.1% |
| 11402 | Removal of noncancer skin growth of body, arms, or legs, 1.1-2.0 cm | Office | 2023 | 16 | 16 | $4,352 | $1,256 | 28.9% |
| 69100 | Biopsy of ear | Office | 2023 | 11 | 11 | $1,841 | $617.86 | 33.6% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 16 | 41 | $205.00 | $30.91 | 15.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 705 | 1,076 | $126,408 | $72,394 | 57.3% |
| 96910 | Therapy procedure using ultraviolet radiation with tar or petroleum jelly application | Office | 2022 | 21 | 555 | $160,950 | $61,890 | 38.5% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 445 | 593 | $77,520 | $26,880 | 34.7% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 274 | 320 | $92,438 | $26,162 | 28.3% |
About Dr. Clive Liu, MD
Dr. Clive Liu, MD is a Dermatology healthcare provider based in Bellevue, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1790793487.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Clive Liu, MD has received a total of $3.0M in payments from pharmaceutical and medical device companies, with $601,275 received in 2024. These payments were reported across 4,552 transactions from 42 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($2.1M).
As a Medicare-enrolled provider, Liu has provided services to 8,788 Medicare beneficiaries, totaling 17,921 services with total Medicare billing of $974,281. Data is available for 4 years (2020–2023), covering 79 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location Bellevue, WA
- Active Since 08/04/2006
- Last Updated 08/10/2018
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1790793487
Products in Payments
- Otezla (Drug) $437,405
- COSENTYX (Biological) $305,876
- TREMFYA (Drug) $268,149
- TALTZ (Drug) $259,211
- DUPIXENT (Biological) $237,844
- SKYRIZI (Biological) $207,892
- Humira (Biological) $134,167
- OPZELURA (Drug) $128,604
- Bimzelx (Biological) $89,759
- Sotyktu (Drug) $69,992
- RINVOQ (Biological) $62,125
- Zoryve (Drug) $61,874
- VTAMA (Drug) $58,114
- Olumiant (Drug) $51,955
- SPEVIGO (Drug) $50,844
- DUPIXENT DUPILUMAB INJECTION (Biological) $42,198
- Tremfya (Drug) $41,470
- CIBINQO (Drug) $28,595
- DUPIXENT (Drug) $22,361
- ATOPIC DERMATITIS - DISEASE (Drug) $21,586
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Bellevue
Sharon Kelly, Md, MD
Dermatology — Payments: $140,377
Dermatology $140,377
Jing Liu, Md, MD
Dermatology — Payments: $38,377
Dermatology $38,377
Deetta Gray, M.d., Faad, Frcpc, M.D., FAAD, FRCPC
Dermatology — Payments: $11,798
Dermatology $11,798
Kieu Dang, Pac, PAC
Dermatology — Payments: $11,502
Dermatology $11,502
Diane Chiu, Md, MD
Dermatology — Payments: $8,139
Dermatology $8,139
Dr. Amanda Norton, Dnp, Arnp, DNP, ARNP
Dermatology — Payments: $7,120
Dermatology $7,120